| Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time M Aleksic, O Dushek, H Zhang, E Shenderov, JL Chen, V Cerundolo, ... Immunity 32 (2), 163-174, 2010 | 292 | 2010 |
| Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations ES Antonarakis, F Shaukat, PI Velho, H Kaur, E Shenderov, DM Pardoll, ... European urology 75 (3), 378-382, 2019 | 171 | 2019 |
| NAADP activates two-pore channels on T cell cytolytic granules to stimulate exocytosis and killing LC Davis, AJ Morgan, JL Chen, CM Snead, D Bloor-Young, E Shenderov, ... Current Biology 22 (24), 2331-2337, 2012 | 150 | 2012 |
| Rational development of high-affinity T-cell receptor-like antibodies G Stewart-Jones, A Wadle, A Hombach, E Shenderov, G Held, E Fischer, ... Proceedings of the National Academy of Sciences 106 (14), 5784-5788, 2009 | 144 | 2009 |
| Quantitating T cell cross-reactivity for unrelated peptide antigens J Ishizuka, K Grebe, E Shenderov, B Peters, Q Chen, Y Peng, L Wang, ... The Journal of Immunology 183 (7), 4337-4345, 2009 | 101 | 2009 |
| Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial E Shenderov, K Boudadi, W Fu, H Wang, R Sullivan, A Jordan, D Dowling, ... The Prostate 81 (6), 326-338, 2021 | 39 | 2021 |
| Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features JW Sidhom, IJ Siddarthan, BS Lai, A Luo, BC Hambley, J Bynum, ... NPJ precision oncology 5 (1), 38, 2021 | 32 | 2021 |
| Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer MC Markowski, E Shenderov, MA Eisenberger, S Kachhap, DM Pardoll, ... The Prostate 80 (5), 407-411, 2020 | 29 | 2020 |
| Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial E Shenderov, AM De Marzo, TL Lotan, H Wang, S Chan, SJ Lim, H Ji, ... Nature medicine 29 (4), 888-897, 2023 | 23 | 2023 |
| Genomic and clinical characterization of pulmonary‐only metastatic prostate cancer: A unique molecular subtype E Shenderov, P Isaacsson Velho, AH Awan, H Wang, N Mirkheshti, ... The Prostate 79 (13), 1572-1579, 2019 | 22 | 2019 |
| T lymphocytes need less than 3 min to discriminate between peptide MHCs with similar TCR‐binding parameters A Brodovitch, E Shenderov, V Cerundolo, P Bongrand, A Pierres, ... European journal of immunology 45 (6), 1635-1642, 2015 | 21 | 2015 |
| Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate-and high-risk prostate cancer E Shenderov, A Demarzo, K Boudadi, M Allaf, H Wang, C Chapman, ... J. Clin. Oncol 36 (15), 10.1200, 2018 | 17 | 2018 |
| 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: preliminary results of phase I cohort expansion E Shenderov, GHG Mallesara, PJ Wysocki, W Xu, R Ramlau, ... Annals of Oncology 32, S657-S659, 2021 | 16 | 2021 |
| Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer AA Mendes, J Lu, HB Kaur, SL Zheng, J Xu, J Hicks, AB Weiner, ... Cancer 128 (12), 2269-2280, 2022 | 15 | 2022 |
| Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction BC Hambley, KJ Norsworthy, J Jasem, JW Zimmerman, E Shenderov, ... Leukemia research 83, 106174, 2019 | 11 | 2019 |
| Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1157-165 tumor-specific peptide E Shenderov, M Kandasamy, U Gileadi, J Chen, D Shepherd, J Gibbs, ... Journal for immunotherapy of cancer 9 (6), 2021 | 10 | 2021 |
| Rational development of high-affinity T-cell receptor-like antibodies (vol 106, pg 5784, 2009) G Stewart-Jones, A Wadle, A Hombach, E Shenderov, G Held, E Fischer, ... Proceedings of the National Academy of Sciences of the United States of …, 2009 | 8 | 2009 |
| Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F] DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation E Shenderov, MA Gorin, S Kim, PT Johnson, ME Allaf, AW Partin, ... Urology Case Reports 17, 22-25, 2018 | 7 | 2018 |
| Reimagining vaccines for prostate cancer: back to the future E Shenderov, ES Antonarakis Clinical Cancer Research 26 (19), 5056-5058, 2020 | 5 | 2020 |
| Targeting B7-H3 in prostate cancer: phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives E Shenderov, AM De Marzo, TL Lotan, H Wang, SJ Lim, ME Allaf, ... J Clin Oncol 40 (16_suppl), 5015, 2022 | 4 | 2022 |
Emmanuel S. Antonarakis, M.D.Clark Endowed Professor of Medicine, University of MinnesotaVerified email at umn.edu
